Estrogen receptor
CA 2302629 C · Owner: Merck & Co. Inc. · Inventors: Wilkinson, Hilary
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to a novel estrogen receptor and to the polynucleotide sequences encoding this receptor. This invention also relates to methods for identifying ligands which bind to this receptor to the ligands so identified, and to pharmaceutical compositions comprising such ligands. This invention also relates to pharmaceutical compositions useful for treating or preventing estrogen receptor mediated diseases or conditions such as abnormal bone , resorption, cardiovascular diseases cancer, or central nervous system , disorders.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 4, 1998 and granted February 20, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 4, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 4, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.